dc.contributor.author | Søraas, Arne Vasli | |
dc.contributor.author | Grødeland, Gunnveig | |
dc.contributor.author | Granerud, Beathe Kiland | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Lind, Andreas | |
dc.contributor.author | Fevang, Børre | |
dc.contributor.author | Murphy, Sarah Louise Mikalsen | |
dc.contributor.author | Huse, Camilla | |
dc.contributor.author | Nygaard, Anders Benteson | |
dc.contributor.author | Steffensen, Anne Katrine | |
dc.contributor.author | Al-Baldawi, Huda | |
dc.contributor.author | Holberg-Petersen, Mona | |
dc.contributor.author | Andresen, Lise Lima | |
dc.contributor.author | Ågnes, Camilla | |
dc.contributor.author | Ranheim, Trine | |
dc.contributor.author | Schanke, Ylva | |
dc.contributor.author | Istre, Mette Stausland | |
dc.contributor.author | Dahl, John Arne | |
dc.contributor.author | Chopra, Adity | |
dc.contributor.author | Dudman, Susanne | |
dc.contributor.author | Kaarbø, Mari | |
dc.contributor.author | Andersen, Jan Terje | |
dc.contributor.author | Vaage, Eline Benno | |
dc.contributor.author | Tran, Trung The | |
dc.contributor.author | Vaage, John Torgils | |
dc.contributor.author | Michelsen, Annika Elisabet | |
dc.contributor.author | Müller, Fredrik | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Halvorsen, Bente Evy | |
dc.contributor.author | Dahl, Tuva Børresdatter | |
dc.contributor.author | Holter, Jan Cato | |
dc.contributor.author | Lund-Johansen, Fridtjof | |
dc.date.accessioned | 2023-02-01T14:17:56Z | |
dc.date.available | 2023-02-01T14:17:56Z | |
dc.date.created | 2022-10-10T09:54:56Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Frontiers in Immunology. 2022, 13, Artikkel 964525. | en_US |
dc.identifier.issn | 1664-3224 | |
dc.identifier.uri | https://hdl.handle.net/11250/3047786 | |
dc.description.abstract | Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Frontiers Media S.A. | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | cellular immunity | en_US |
dc.subject | Breakthrough infection | en_US |
dc.subject | antibody | en_US |
dc.subject | human | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | vaccine | en_US |
dc.title | Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2022 Søraas, Grødeland, Granerud, Ueland, Lind, Fevang, Murphy, Huse, Nygaard, Steffensen, al-Baldawi, Holberg-Petersen, Andresen, Ågnes, Ranheim, Schanke, Istre, Dahl, Chopra, Dudman, Kaarbø, Andersen, Vaage, Tran, Vaage, Michelsen, Müller, Aukrust, Halvorsen, Dahl, Holter and LundJohansen. | en_US |
dc.subject.nsi | VDP::Medisinsk mikrobiologi: 715 | en_US |
dc.subject.nsi | VDP::Medical microbiology: 715 | en_US |
dc.source.volume | 13 | en_US |
dc.source.journal | Frontiers in Immunology | en_US |
dc.identifier.doi | 10.3389/fimmu.2022.964525 | |
dc.identifier.cristin | 2059925 | |
dc.relation.project | Norges forskningsråd: 312780 | en_US |
dc.relation.project | Norges forskningsråd: 324274 | en_US |
dc.relation.project | Helse Sør-Øst RHF: 2019067, 2021071, 2021047, 33612, 2021087, 10357, 2017092 | en_US |
dc.relation.project | EU – Horisont Europa (EC/HEU): 848099 | en_US |
dc.relation.project | EU – Horisont Europa (EC/HEU): 71029 | en_US |
dc.relation.project | Oslo universitetssykehus HF: Fredrik Müller | en_US |
dc.source.articlenumber | 964525 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |